Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | GUCY1A1 | Q02108 | 17/20 | 0.45 |
| ▸ | GUCY1B1 | Q02153 | 17/20 | 0.45 |
| ▸ | PDE5A | O76074 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23161951 | 0.90 | KCNH2 (0.49) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL20534383 | 0.90 | ADORA3 (0.49) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL30937506 | 0.89 | ADORA3 (0.50) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL23161959 | 0.89 | ADORA3 (0.50) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL23161907 | 0.88 | ADORA3 (0.45) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL23161918 | 0.87 | ADORA3 (0.41) | ADORA3KCNH2GUCY1A1GUCY1B1 | |
| SCHEMBL248357 | 0.86 | ADORA3 (0.69) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL31166518 | 0.86 | ADORA3 (0.69) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL23161925 | 0.86 | ADORA3 (0.39) | ADORA3KCNH2GUCY1A1GUCY1B1 | |
| SCHEMBL23161917 | 0.85 | ADORA3 (0.41) | ADORA3KCNH2GUCY1A1GUCY1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118221651-A | Crystal forms of fluorine substituted indazole compound and use thereof | 广东东阳光药业股份有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-118221649-A | Crystal forms of fluorine substituted indazole compound and use thereof | 广东东阳光药业股份有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-118221650-A | Crystal forms of fluorine substituted indazole compound and use thereof | 广东东阳光药业股份有限公司 | 2024-06-21 | — | — | CN | disclosed |
| EP-3609883-B1 | FLUORINE-SUBSTITUTED INDAZOLE COMPOUNDS AND USES THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2022-06-29 | — | — | EP | disclosed |
| US-11242335-B2 | Fluorine-substituted indazole compounds and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-02-08 | — | — | US | disclosed |
| US-20210101882-A1 | FLUORINE-SUBSTITUTED INDAZOLE COMPOUNDS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-04-08 | — | — | US | disclosed |
| EP-3609883-A1 | FLUORINE-SUBSTITUTED INDAZOLE COMPOUNDS AND USES THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2020-02-19 | — | — | EP | disclosed |
| WO-2018188590-A1 | FLUORINE-SUBSTITUTED INDAZOLE COMPOUNDS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11242335-B2 | Fluorine-substituted indazole compounds and uses thereof | GUCY1B2, GUCY1A2, PDE3A | ADORA3 46/4885KCNH2 485/4885GUCY1A1 8/4885 |
| US-20210101882-A1 | FLUORINE-SUBSTITUTED INDAZOLE COMPOUNDS AND USES THEREOF | PDE3A, PDE3B, PDE5A | ADORA3 43/4885KCNH2 835/4885GUCY1A1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.